Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Dongjin Road Site) – FDA 483
Jiangsu Hengrui Pharmaceuticals CO. LTD. received a Form 483 with nine observations during an inspection from August 14-29, 2023. The observations highlight significant deficiencies across laboratory controls, aseptic processing, environmental monitoring, and batch recordkeeping, indicating a lack of robust quality systems for sterile drug product manufacturing. Issues include unrepresentative sampling, inadequate sterility testing procedures, rewritten logbook entries, turbulent airflow in aseptic areas, and insufficient contamination prevention and monitoring.
- Product type
- drugs
- Office
- Office of Partnerships
- Person
ID · 6a83eb5d-8c88-4934-b86a-ab09a2182318
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.